Stingthera to Participate at ACCESS CHINA Biotech Forum

By Yafo Life Science

September 18th, 2021 (Shanghai) — We are glad to announce that Lanny Sun, Chairman of Stingthera, has been invited to showcase at ACCESS CHINA Biotech Forum on Thursday, September 23, 2021 at 9:00 p.m. ET. ACCESS CHINA Biotech Forum is the largest online corporate access event between China and the western biopharma industry.

If you are interested in listening to the live event, please register at https://biotochina.org/register/

About Stingthera

Stingthera is a US based biotech company involved in the development of it’s wholy ownd STING agonist, SNX281, for oncology and infectious disease. SNX 281 is currently undergoing P1 clinical trials in the US with plans to expand to Europe and China in the future.

About ACCESS CHINA

ACCESS CHINA is the most effective deal-making platform for Western pharma and biotech leaders looking to enter or expand in the Chinese market. ACCESS CHINA creates invaluable BD opportunities by directly connecting and meeting with the right partners for development, licensing or commercial collaborations. View more information at https://biotochina.org/access-china-forum/

ACCESS CHINA Upcoming event

“ACCESS CHINA Biotech Forum @ The 16^th China Pharma & MedTech BD Forum” will be held in Suzhou and online on September 23^rd-30^th, 2021. This conference is the largest ACCESS CHINA event of the year.

More information